Pfizer Inc (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) said they were scrapping further studies of one of the most anticipated experimental Alzheimer's disease treatments after the drug failed to help patients with the memory-robbing condition in a second high-profile late stage clinical trial.
The companies said they would discontinue all other studies of the drug bapineuzumab, including two more late stage trials and follow-up extension studies, in patients with mild to moderate Alzheimer's.
Continue Reading Below
The result marked the second such failure announced in recent weeks and was especially disappointing as bapineuzumab had been given a better chance of success in the patients studied in the second trial.
Bapineuzumab failed to improve cognitive or functional performance compared with placebo in patients who did not carry a variation of a gene called ApoE4, according to initial results of the Phase III study released on Monday.
Pfizer on July 23 announced the failure in the first of four high-stakes trials -- that in patients with the ApoE4 gene variation. That trial was considered more of a long-shot based on poor results in earlier trials, but hopes were high that the data would prove more encouraging in ApoE4 non-carriers.
"We are obviously very disappointed in the outcomes of this trial. We are also saddened by the lost opportunity to provide a meaningful advance for patients afflicted with mild-to-moderate Alzheimer's disease and their caregivers," Steven Romano, head of Pfizer's Medicines Development Group, said in a statement.
J&J said it would take a charge of between $300 million and$400 million against earnings in the third quarter related to discontinuation of the bapineuzumab Phase III clinical trial program.